Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy. The main questions it aims to answer are: * Is patient quality of life improved by using the telemonitoring platform? * Are patients hospitalized less frequently when using the telemonitoring platform? * Is the patient overall survival improved by telemonitoring ? Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care. Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana pisemna zgoda na udział w badaniu (może być podpisana przez zaufaną osobę, jeśli pacjent nie jest w stanie tego zrobić)
- •Wiek 18 lat lub więcej
- •Rozpoznany potwierdzony biopsją nowotwór piersi z przerzutami typu triple negative (receptory estrogenowe i progesteronowe poniżej 10%, brak receptorów Her2)
- •Spodziewana długość życia powyżej 6 miesięcy według oceny lekarza
- •Rozpoczęcie pierwszej linii leczenia systemowego rozpoznanego nowotworu przerzutowego
- •Dobry stan ogólny (ECOG 0-2)
- •Dostęp do komputera, tabletu lub smartfona z dostępem do internetu
- •Zdolność i chęć do wypełniania ankiet przez internet przez cały czas trwania badania
✗ Disqualifies
- •Uczestnictwo w innym badaniu klinicznym wykorzystującym telemonitorowanie
- •Niezdolność fizyczna lub psychiczna do używania aplikacji do telemonitorowania, według oceny lekarza
- •Pozbawienie wolności, areszt ochronny lub poddanie się opiece zastępczej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (51)
Institut de Cancérologie des Hauts-de-France (ICHF)
Arras, France
Centre Hospitalier d'Auxerre
Auxerre, France
Sainte Catherine - Institut du Cancer Avignon Provence
Avignon, France
CH Aunay-Bayeux
Bayeux, France
Centre Hospitalier Simone Veil de Beauvais
Beauvais, France
ICHF - Centre Pierre Curie
Beuvry, France
Hôpital Simone Veil de Blois
Blois, France
Polyclinique bordeaux nord
Bordeaux, France
Centre Hospitalier Fleyriat
Bourg-en-Bresse, France
Centre de Cancérologie Privé de Caen Maurice Tubiana
Caen, France
Centre Francois Baclesse
Caen, France
Centre hospitalier de Carcasonne
Carcassonne, France
Recherche Oncologie Clinqiue 37 (ROC 37)
Chambray-lès-Tours, France
CH de Cholet
Cholet, France
CH Colmar
Colmar, France
Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
Creil, France
Centre Georges François Leclerc
Dijon, France
Institut Andrée Dutreix
Dunkirk, France
CH Annecy Genevois
Épagny, France
Centre Hospitalier Intercommunal de Fréjus Saint Raphael
Fréjus, France
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, France
CHU de la réunion
La Réunion, France
Clinique Sainte Clotilde
La Réunion, France
Groupe Hospitalier de La Rochelle-Ré-Aunis
La Rochelle, France
CHU Grenoble Alpes
La Tronche, France
Centre Hospitalier Louis Pasteur
Le Coudray, France
Centre Hospitalier Le Mans
Le Mans, France
Centre Hospitalier Emile Roux
Le Puy-en-Velay, France
GHBS Lorient
Lorient, France
Centre Leon Berard
Lyon, France
Clinique de la Sauvegarde
Lyon, France
Hôpital Privé Jean Mermoz
Lyon, France
Institut Paoli Calmettes
Marseille, France
CHI de Mont-de-Marsan et du Pays des Sources
Mont-de-Marsan, France
Centre de Cancérologie du Grand Montpellier
Montpellier, France
Hôpital Privé du Confluent
Nantes, France
Clinique Ambroise-Pare Hartmann
Neuilly-sur-Seine, France
Hôpital Américain de PARIS
Neuilly-sur-Seine, France
CHU de Nimes
Nîmes, France
CHR Orleans
Orléans, France
CHP Sainte-Marie
Osny, France
Diaconesses Croix Saint-Simon Hospital Complex
Paris, France
Centre hospitalier de Pau
Pau, France
CARIO - Hopital Privé des Cotes d'Armor
Plérin, France
CHU de Poitiers
Poitiers, France
Institut Godinot
Reims, France
Clinique Mathilde - Les Hôpitaux Privés Rouennais
Rouen, France
CHU de Saint-Etienne
Saint-Etienne, France
Hia Begin
Saint-Mandé, France
CHU de Tours
Tours, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Trial contact
Adeline POITOU
Jérôme LEMONNIER, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.